Background: Transcatheter aortic valve implantation has become an option for high-surgical-risk patients with aortic valve disease.
Introduction
Transcatheter aortic valve implantation (TAVI) was first introduced in 2002 as an alternative treatment for patients with aortic stenosis (AoS) at extreme risk for surgery. 1 As from 2008, it has become available in Brazil, in parallel with major technological advances and the publication of large-scale randomized clinical trials demonstrating the benefits of this treatment in the relief of symptoms as well as in mortality reduction. [2] [3] [4] [5] [6] TAVI indications also expanded to the treatment of bioprosthetic valve dysfunction and selected cases of aortic regurgitation.
In order to make concepts uniform and establish comparable parameters, a group of highly regarded authors, under the name of Valve Academic Research Consortium (VARC), proposed procedure-related criteria of success and complications. 7, 8 Despite its importance, many authors were initially reluctant to adhere to the VARC criteria, possibly because their strict concepts could lead to the perception of unfavorable results.
The first case series of TAVI in the State of Rio de Janeiro was published in 2010, 9 and these patients as well as the progression of the technique have been followed up ever since, thus adjusting the assessments to the VARC criteria. In this study, we evaluated the success rate, morbidity and mortality throughout in-hospital and one-year follow-up in a 5-year-experiece with TAVI.
Methods study population
Prospective cohort study of consecutive cases of TAVI between July 2009 and February 2015. TAVI was indicated Transcatheter aortic valve implantation-related morbidity and mortality Arq Bras Cardiol. 2016; 106(6):519-527 for patients with severe heart valve stenosis, severe aortic regurgitation or bioprosthetic aortic valve dysfunction at a high surgical risk. Demographic, echocardiographic, laboratory and procedural data were assessed during the in-hospital and one-year outpatient follow-up. Heart failure symptoms were classified according to the New York Heart Association (NYHA) criteria, and the success and complications criteria were based on VARC 2: hospital discharge, aortic regurgitation < grade 2/4, mean left ventricular-aortic pressure gradient (LV-Ao) < 20 mmHg, and use of only one prosthesis. Definitions of complications by VARC are described elsewhere, and include criteria of acute myocardial infarction (AMI) and stroke 7 . Chronic renal failure (CRF) was defined as an estimated glomerular filtration rate < 60 mL/minute using the Cockroft and Gault formula. Acute renal failure (ARF) was defined by the Acute Kidney Injury Network (AKIN) classification system as follows: stage 1, if serum creatinine (Cr) elevation between 1.5 and 1.99 times; stage 2, if between 2 and 2.99 times; and stage 3, if greater than 3 times or need for dialytical support. 
Pre-procedural assessment
Indications were evaluated by the cardiology team, which was comprised of cardiology clinicians, interventionists, surgeons, anesthetists, and echocardiographers. Once TAVI was indicated, all patients would undergo coronary angiography and assessment of coronary artery disease, with occasional indication of coronary angioplasty, which was left to the discretion of the surgeon. Aorta and iliac branches were measured by angiography and/or CT angiography to define the prostheses and vascular approach to be used.
Procedural technique
All patients received antibiotic prophylaxis with cefazolin 2 g prior to the intervention. Acetylsalicylic acid (ASA) 200 mg and clopidogrel 300 mg were administered on the day before the procedure, except when contraindicated in the cases of low platelet count < 80 x 10 3 /mm 3 or other comorbidities. The procedures were performed in the hemodynamics laboratory or in the hybrid room, under sedation or general anesthesia, and transesophageal echocardiography (TEE) monitoring. Temporary transvenous pacemakers were implanted to help in balloon valvuloplasty and/or prosthesis implantation, by means of induction of tachycardia, and were kept on the on-demand mode for 48 hours. The choice of of whether or not to pre-dilate the valve was left to the surgeon's discretion. The prostheses used were the self-expanding CoreValve ® (Medtronic, Minneapolis, MN) and the balloon-expanding Edwards-SAPIEN XT ® (Edwards Lifesciences, Irvine, CA). After TAVI, the patients were sent to the intensive care unit and underwent daily laboratory assessments in the first 7 days.
Late follow-up
The outpatient follow-up was performed via phone calls at 30 days, 6 months and 1 year, and clinical, echocardiographic and adverse events data were recorded.
The study was approved by the local Research Ethics Committee under registration 423, on April 8, 2011. All patients gave written informed consent to participate in the study. Table 2 . Blood transfusion prior to the procedure was made in eight patients (5.8%).
Statistical analysis
Findings of the baseline TEE are shown in Table 3 . Ejection fraction (EF) < 50% was found in 26.5% of patients, and bicuspid aortic valve, in 2.9%. A mean LV-Ao gradient < 40 mmHg was found in 46/131 cases (35.1%).
In addition to angiography of the iliac and femoral arteries, CT angiography of these arteries was also performed in 17.6% of individuals. Coronary percutaneous interventions were performed prior to TAVI in eight patients (5.9%) and peripheral percutaneous interventions in four (2.95%) (one in carotid, two in iliac and one in subclavian artery). The vascular access was the femoral artery in 129 cases (94.9%), left subclavian artery in six (4.4%), and aorta in one (0.8%). All vascular accesses were made via arteriotomy and further surgical vascular suture. A hemostasis device was used in only one case.
Heart valve pre-dilatation was performed in 110 patients (80.9%) and direct implantation, in 26 (19.1%). The self-expanding CoreValve ® prosthesis was implanted in 132 patients (97%) and the balloon-expanding Edwards SAPIEN XT ® prosthesis, in four (3%). VARC2 success was achieved in 83.1% of cases. After TAVI, the invasive LV-Ao gradient dropped from 54.8 ± 25.5 mmHg to 1.7 ± 3.4 mmHg (p < 0.001). An additional intervention for correction of paraprosthetic aortic valve regurgitation was required in 55 cases (40.4%); balloon post-dilatation in 48 (35.5%); additional prosthesis implantation in six (4.4%); and prosthesis repositioning by loop traction in one (0.7%). Post-TAVI aortic regurgitation was considered absent in 53 patients (39%), mild in 71 (52.2%) and moderate in eight (5.9%) -all due to paraprosthetic regurgitation.
ARF occurred in 15.4% of patients, and 2.2 reached stage 3. The volume of contrast medium used was 143.0 ± 37.1 mL. There was one case of ischemic stroke with no sequela. There was no procedure-related AMI.
New permanent pacemaker implantation was required in 29/118 cases (24.5%).
The blood transfusion rate after TAVI was 21.3% (29 patients), of which eight received transfusion of two or three units of red blood cell concentrate, and ten received four or more. Perioperative bleeding related to the vascular access occurred in three cases; however, blood transfusions were performed for other complications such as LV perforation and hemothorax.
The length of hospital stay was 7 ± 22 days. Prolonged hospital stay (> 7 days) occurred in 51/125 cases (40.8%), with a maximum of 212 days.
Perioperative mortality rate was 1.5%; 30-day mortality was 5.9%, and in-hospital mortality was 8.1%. When the subgroup of in-hospital death was compared to that of patients discharged, we observed that the first showed higher baseline BNP [770 pg/mL (320-1.260) vs 227 pg/mL (123-553); p = 0.017]; a higher incidence of pulmonary arterial hypertension (54.6% vs 21.6%; p = 0.024); CRF (81.8% vs 51.2%; p=0.048); and ARF (45.5% vs. 11.2%; p = 0.008). Post-dilatation (70% vs. 35.2%; p = 0.034) and blood transfusion after TAVI (90.9% vs. 17.1%; p < 0.0001) were also more frequent. In the first week, there was higher Transcatheter aortic valve implantation-related morbidity and mortality Arq Bras Cardiol. 2016; 106(6):519-527
Discussion
This article describes the 5-year experience on self-expanding prosthetic heart valve implantation via femoral artery by means of arteriotomy in a medical center that has one of the highest case series in Brazil. Throughout this period, important conceptual changes had the following consequences: (1) lower tolerance to the presence of aortic regurgitation after the procedure; (2) adoption of general anesthesia associated with TEE monitoring, which enabled a more accurate quantification of the degree of paraprosthetic regurgitation and assessment of structural complications; (3) performance of procedures in a hybrid room; and (4) formalization of a team of cardiology specialists to share decision making.
The population characteristics are not different from those presented in most of the registries, [10] [11] [12] [13] [14] including the national registry. 15 Procedural success by VARC2 criteria achieved 83.1% in our cohort, whereas in the national registry it reached 76.3%. Currently, the literature demands considerable attention to the definitions adopted in the short-term results. The VARC2 criteria for device-implantation success include a mean transprosthetic gradient < 20 mmHg, absent or mild aortic regurgitation, and single-prosthesis implantation. As an example, Thyregod et at. 16 recently reported to have adopted VARC2 criteria and found a 97.9% procedural success rate, although they had described the presence of moderate aortic regurgitation in 14.5% of cases, which would reduce the success rate to 83.4%.
The finding of an overall 30-day mortality of 5.9% in a group of very severely ill patients (mean STS of 15%) is a relevant fact. Registries from other countries showed 30-day mortality rates ranging from 5.2% to 10%, 10-12 with 9.1% in the Brazilian national registry. 15 Likewise, we should take care when comparing these results, once the VARC2 criteria recommend the description of in-hospital mortality, and not of 30-day mortality. In this case-series, this variation implied a 2.2% absolute increase, because three cases showed clinical complications that resulted in multiple organ failure and death after 1 month. To better understand the in-hospital course, in keeping with VARC updating, this short-term analysis was carried out using in-hospital mortality, while investigating in-hospital and one-year mortality-associated variables.
Independent factors associated with in-hospital mortality were the presence of pulmonary arterial hypertension and post-TAVI blood transfusion. Pulmonary arterial hypertension is one of the clinical risk factors for early death, regardless of procedural complications 17, 18 like CRF, 19, 20 which, in this analysis, was associated with early mortality. Blood transfusion was the most important independent variable for in-hospital mortality, although no distinction was made regarding its indication. We could speculate that this is a marker of severity common to three clinical situations: long intensive care unit stay, 21 previous anemia followed by minor bleeding, [22] [23] [24] or significant perioperative bleeding. 25 The one-year accumulated overall mortality was 18.3%, one third of which was cardiovascular mortality. The independent (Table 4) . After logistic regression analysis, blood transfusion after TAVI (p = 0.0003) and pulmonary arterial hypertension (p = 0,036) were identified as independent predictors of in-hospital death ( Table 5 ).
The follow-up lasted 2.5 ± 1.4 years. Progression of symptoms according to NYHA functional classes is shown in Figure 1 .
Accumulated overall one-year mortality was 18.3% (20/109) (Figure 2 ), of which cardiovascular mortality accounted for seven cases (two sudden deaths, one AMI for stent thrombosis, one for heart failure, two for hemorrhagic stroke and one for LV perforation When the subgroup of one-year death was compared to the group of survivors, we observed that the first group showed, among the pre-procedural characteristics, higher rates of chronic obstructive pulmonary disease (30% vs 6.7%; p = 0.008); logistic euroSCORE [31% (16- risk factors for one-year mortality were post-TAVI blood transfusion and peak CRP. Escarcega et al. reported 37% of blood transfusion and, in additon to the increase in in-hospital mortality, they also verified an increase in one-year mortality in this subgroup (28% vs 13%; p = 0.001).
22
Like in coronary interventions, in TAVI there is a complex association between vascular complications, bleeding and blood transfusion, with the development of ARF and Systemic Inflammatory Response Syndrome (SIRS) -the latter being able to occur in a disproportionate fashion in relation to the triggering events described. Sinning et al. 26 described that SIRS occurred in 40.1% of TAVI cases and was associated with higher 30-day mortality in addition to being an independent predictor of one-year mortality (hazard ratio -HR = 4.3; p < 0.001). The biomarker most frequently used in clinical practice for the assessment of SIRS is CRP, with a peak around day 3 after TAVI. 27 Peak CRP in the in-hospital death subgroup was twice higher than that found among survivors.
The access was exclusively surgical, aiming to minimize vascular complications and bleedings. However, Bernardi et al., 28 compared the percutaneous and surgical accesses and did not identify differences between vascular complications, bleeding, 30-day mortality or one-year mortality, although they had found a tendency toward a higher frequency of peripheral vascular disease in the surgical access group (16.8% vs10.4%; p=0.07). 28 In the national registry, the percutaneous access was finalized with a hemostasis device in 45.6% of cases. 15 After the first 30 cases, the anesthetic regimen was changed from sedation to general anesthesia, incorporating three-dimensional TEE to the procedure. With this strategy, we aimed to measure the valve annulus in the procedure room, instead of previously using CT angiography, thus having the benefit of reducing nephrotoxicity. This strategy permits a thorough assessment of the degree of paraprosthetic regurgitation. In the Brazilian registry, as well as in our cohort, the use of TEE was associated with lower mortality, 14 although this finding could merely have reflected our learning curve.
When the valve implantation technique was assessed, we observed that the pre-dilatation rate of 78.9% among our cases was higher than the 61% of the national registry.
14 Our perception is that there was a tendency of direct implantation in the more severe cases to avoid the pacemaker-induced tachycardia maneuver.
The prognostic impact of moderate or severe paraprosthetic aortic regurgitation was a concept adopted as from 2011. 8 Only 5.9% of cases of the present study showed this type of post-procedural complication, whereas other studies with predominance of self-expanding valves described rates between 10% and 15%. 4, 16, 29 The fact that intervention was made in 40% of cases shows an aggressive management of paraprosthetic aortic regurgitation when compared to 16.1% to 26.5% of interventions described by other authors. 23, 30 Maybe for this reason, post-TAVI moderate aortic regurgitation was not predictive of poor prognosis in this study. However, we cannot fail to mention that post-dilatation was more frequent in the in-hospital death group, even with no directly related complications having been identified. This finding could reflect a selection bias of a subgroup with a less favorable anatomy. Alternatively, we should remember that pre-and post-balloon dilatation are performed under pacemaker-induced tachycardia, and this leads to systemic hypoperfusion, which, in turn, had been previously related to SIRS. 26 The incidence of ARF was lower in comparison to a mean of 20% of other case series. 20, 30 Sinning et al 29 observ ed that, in patients undergoing CoreValve® implantation, ERF correlated with peripheral vascular disease, SIRS and residual aortic regurgitation, but not directly with volume of contrast medium. Nuis et al. 31 observed that the number of blood transfusions within the first 24 hours is the main risk factor for ARF, which also correlated with peripheral vascular disease, heart failure, and leukocytosis within the first 72 hours. Thus, ARF seems to correlate with hemodynamic instability, especially in the context of bleeding and blood transfusion, with further SIRS.
The virtual absence of stroke during hospital stay was much lower than the 4 to 5% described in other studies. 3, 32 We should point out that, in our protocol, antiplatelet agents are previously administered, and a careful technique is observed in the manipulation of the valve with the guidewire, in addition to a strict control of heparinization.
Management of coronary artery disease is another key issue, because it is present in half the cases of AoS. The extent of myocardial infarction and its possible relation to ventricular dysfunction suggests that it plays a role in the outcome and, currently, revascularization strategies are controversial. 33 The strategy adopted was to perform revascularization in the cases in which a large ischemic area had been estimated by coronary angiography. In this cohort, there was no case of procedure-related AMI, which may suggest that this is an adequate strategy.
Limitations
This study reflected the real-life practice, with inclusion of patients that would have been otherwise excluded in randomized studies. Because it is a prospective cohort, a selection bias cannot be ruled out. Despite the significant number considering the national figures, our case series is small compared to international registries in which predictors of poor prognosis were identified. Additionally, because of the sample size, some variables such as ARF stage or blood transfusion volume could not be stratified, with the purpose of more accurately predicting adverse events. The follow-up by phone calls made it difficult to have a consistent late outpatient assessment of aortic regurgitation and ventricular dysfunction.
Conclusion
Transcatheter aortic valve implantation in patients with severe aortic valve disease and at high surgical risk was Transcatheter aortic valve implantation-related morbidity and mortality Arq Bras Cardiol. 2016; 106(6):519-527 performed with a high success rate and low mortality. Relief of symptoms and one-year survival were high despite the severity of disease. Blood transfusion was associated with in-hospital and one-year mortality. Peak C-reactive protein was associated with one-year mortality. 
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